The post Events This Week That Could Make or Break Bitcoin, Ethereum, and XRP Prices appeared first on Coinpedia Fintech News This week could be crucial for theThe post Events This Week That Could Make or Break Bitcoin, Ethereum, and XRP Prices appeared first on Coinpedia Fintech News This week could be crucial for the

Events This Week That Could Make or Break Bitcoin, Ethereum, and XRP Prices

2026/01/06 00:03
3 min read
Crypto News

The post Events This Week That Could Make or Break Bitcoin, Ethereum, and XRP Prices appeared first on Coinpedia Fintech News

This week could be crucial for the crypto market. Several US economic reports and Federal Reserve comments are lined up, and they may decide whether Bitcoin, Ethereum, and XRP among other tokens continue rising or face fresh pressure.

Right now, markets are not trading on hope or hype. They are reacting to economic data, what it means for the Federal Reserve, and how it affects liquidity. That makes this week especially important for crypto investors.

Monday Sets the Tone With Manufacturing Data

The week begins on Monday, January 5, with the release of the ISM Manufacturing report. This data gives an early signal about how strong or weak the US economy is. A stronger reading could support risk assets, while weak data may raise concerns about slowing growth.

Tuesday Shifts Focus to Services and the Fed

On Tuesday, January 6, attention turns to ISM Services, which is more important than manufacturing right now because services drive most of the US economy. The same day, comments from Fed official Tom Barkin will be closely watched. 

Wednesday Is the Most Important Midweek Test

Wednesday, January 7, is packed with events. The ADP jobs report and job openings data will give insight into the labor market. Strong jobs data could delay rate cuts, while weakness may support easier policy.

On the same day, Fed Vice Chair Michelle Bowman will speak. Her comments on regulation, liquidity, and the economy could heavily influence market sentiment. Many traders see Wednesday as the most important day before Friday’s big report.

Thursday Looks Quiet but Still Matters

On Thursday, January 8, the market gets jobless claims and consumer credit data. These reports usually don’t move markets much, but if they show rising stress, investors could quickly turn cautious.

Friday’s Jobs Report Could Decide the Week

Everything leads into Friday, January 9, when the Non-Farm Payrolls, unemployment rate, and wage data are released. This report often shapes expectations for interest rates and liquidity. A hot report could pressure crypto, while softer data may fuel another rally.

Where Bitcoin, Ethereum, and XRP Stand Now

Bitcoin has continued its steady recovery and is trading near $92,782. It is up 6.35% over the past week, showing strong confidence after recent volatility. However, Bitcoin is still about 26% below its October 2025 all-time high.

Ethereum is outperforming Bitcoin this week. ETH is trading around $3,157, up 7.86% in seven days. While still well below its 2025 peak, Ethereum’s momentum appears stronger, helped by increased activity in DeFi and NFTs.

XRP is the standout performer. The token has jumped 16.83% this week and is trading near $2.12. Although XRP remains far from its all-time high, recent price action shows new interest, possibly linked to the broader bullish sentiment.

Market Trend Remains Constructive

Overall, Bitcoin, Ethereum, and XRP are all moving higher going into the week. Technical indicators also support the bullish tone, with momentum improving and selling pressure fading. For now, bulls remain in control, but upcoming economic data could quickly change the picture.

This week’s events may not just move prices for a day or two. They could shape the direction of crypto markets for the rest of January.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.4234
$1.4234$1.4234
-1.56%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26